Get started
AEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INC

AEQUUS PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Technicals

AQS chart

Key stats

Market capitalization
‪1.99 M‬CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.025CAD
Net income
‪−3.21 M‬CAD
Revenue
‪1.38 M‬CAD
Shares float
‪112.80 M‬
Beta (1Y)
0.51

About AEQUUS PHARMACEUTICALS INC

Sector
Health Technology
CEO
Douglas Glen Janzen
Headquarters
Vancouver
Website
aequuspharma.ca
Employees (FY)
15
Founded
2013
ISIN
CA0076361033
FIGI
BBG0089LFZQ4
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of AQS is 0.00 CAD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NEO exchange AEQUUS PHARMACEUTICALS INC stocks are traded under the ticker AQS.
AEQUUS PHARMACEUTICALS INC is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track AEQUUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
Like other stocks, AQS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AEQUUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
AQS reached its all-time high on Mar 2, 2017 with the price of 0.45 CAD, and its all-time low was 0.00 CAD and was reached on Mar 22, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 15.00 employees. See our rating of the largest employees — is AEQUUS PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AEQUUS PHARMACEUTICALS INC EBITDA is ‪−2.44 M‬ CAD, and current EBITDA margin is −171.64%. See more stats in AEQUUS PHARMACEUTICALS INC financial statements.